Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: July 24, 2020
Expires: July 24, 2021
60 minutes to complete

Accredited By

Target Audience

This activity is intended for rheumatologists, internal medicine specialists, nurses, and other allied health-care professionals, as well as patients and caregivers interested in treatment advances for rheumatoid arthritis (RA).

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Assess characteristics of patients with RA that may be predictive of poor response to biologic treatment and assess opportunities with novel therapies
  • Evaluate clinical efficacy, safety, and tolerability of biologic and small molecule drugs for the treatment of RA
  • Implement treat-to-target strategies for refractory patients considerate of disease activity, treatment response, and other patient-specific factors

Activity Description

How can clinicians be assured they have the most up-to-date information for improving their patients’ outcomes in RA care? In this clinical commentary, leading infectious disease expert Kevin Winthrop, MD, MPH, and Rheumatology experts Philip Mease, MD, MACR, and William F.C. Rigby, MD, discuss the latest evidence, safety data, and potential roles with the available and emerging JAK inhibitors, as well as current treat-to-target RA paradigms.

Because the patient plays such a critical role in shared decision-making, this activity will also include patient ambassadors sharing their perspectives, experiences, and treatment goals.

Bonus supplemental material includes:

  • Understanding Discordance in RA Care
  • Patient Perspectives on Shared Decision-Making
  • What Patients with RA Want Their Rheumatologists to Know
  • EULAR 2020 RA Updates

Statement of Educational Need

Rheumatoid arthritis (RA) is a debilitating, inflammatory condition that has significant ramifications on a patient’s quality of life, risk for disability, morbidity, and mortality. The range of disease-modifying antirheumatic drugs (DMARDs) has shifted and expanded dramatically for RA over the last 20 years, facilitating the use of a treat-to-target approach. With multiple classes of biologic and targeted therapies now approved for RA and more biosimilars coming to market as patents expire on older biologic agents, therapy decisions are rapidly becoming more complex, and physicians may be struggling to keep up.

As the availability of these novel agents complicates treatment decisions for RA, physicians need to properly evaluate treat-to-target strategies for their patients and therapy selection that should be made in concert with patients, after reviewing their treatment history, route of administration, and lifestyle preferences. In addition, rheumatologists and clinicians who treat or diagnose RA need to enhance their understanding of the latest treatments and best practices to manage their patient populations effectively. Physicians need to take an active approach to apply the current evidence in practice with their RA patients and alleviate the burden the patient faces.


Clinical commentary highlights includes:

  • Available and emerging JAK inhibitors
  • Tactics for patients who may have a poor response to biologic treatment
  • Role and adverse event management of small molecule drugs 
  • The latest treat-to-target paradigms


Kevin Winthrop, MD, MPH
Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Science University
Portland, OR


Philip Mease, MD, MACR
Director, Rheumatology Research Division
Swedish Medical Center/Providence-St. Joseph Health
Clinical Professor, University of Washington School of Medicine
Seattle, WA

William F.C. Rigby, MD
Professor of Medicine, Microbiology and Immunology
Division of Rheumatology
Vice Chairman, Academic Affairs
Department of Medicine
Dartmouth Medical School
Dartmouth-Hitchcock Medical Center
Lebanon, NH

Patient Ambassadors

Kelly O'Neill
Founder, Rheumatoid Arthritis Warrior Community
Founder, Rheumatoid Patient Foundation

Shannon Young, EdD
Executive Director,
Rheumatoid Patient Foundation

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

The following financial relationships have been provided:

Kevin Winthrop, MD, MPH (Chair)
Sources of Funding for Research: Bristol Myers Squibb and Pfizer Inc.
Consulting Agreements: Abbvie, Galapagos, Gilead Sciences, Inc., GlaxoSmithKline, Lilly, Pfizer Inc., Roche, UCB

Philip Mease, MD, MACR (Faculty)
Sources of Funding for Research: Abbvie, Amgen, Bristol Myers Squibb, Galapagos, Gilead Sciences, Inc., Janssen, Lilly, Novartis, Pfizer Inc., Sun Pharmaceutical Industries Ltd., UCB
Consulting Agreements: Abbvie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Galapagos, Gilead Sciences, Inc., GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer Inc., Sun Pharmaceutical Industries Ltd., UCB
Speakers' Bureau: Abbvie, Amgen, Bristol Myers Squibb, Genentech, Janssen, Lilly, Novartis, Pfizer Inc., UCB

William F.C. Rigby, MD (Faculty)
Clinical Trials: Abbvie, Bristol Myers Squibb, Gilead Sciences, Inc., Pfizer Inc.
Consulting Agreements (Occasional): Abbvie, Bristol Myers Squibb, Gilead Sciences, Inc., Pfizer Inc.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use:
Baricitinib, filgotinib, upadacitinib as well as JAK inhibitors under investigation for RA

Patient Ambassador Disclosures

Kelly O'Neill and Shannon Young, EdD, have no financial relationships.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)

Instructions for Receiving Credit

This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions About the Activity

For questions, contact Michelle Forcier at 

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.